- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05667701
Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study (SIRA)
March 29, 2024 updated by: Rajesh Kumar
The goal of this clinical trial is to compare soy isoflavones to placebo in children who at risk of asthma and have a genetic variation which results in them making more of a pro-inflammatory protein, plasminogen activator inhibitor-1.
The main questions this trail seeks to answer is: will soy isoflavones decrease wheezing episodes in these children when given in the first year of life.
Participants will be asked to ingest soy isoflavone or placebo twice daily mixed into a liquid or puree vehicle for 7 months from randomization.
There will be 3 mandatory in-person visits, and 6 virtual visits in the first year.
There will also be 11 monthly questionnaires and 1 in person visit in the observation year.
Participants will have 4 nasal swabs, 3 blood draws, and also provide 4 stool samples over the course of the study.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study is designed as a single site, randomized, quadruple-masked, placebo-controlled, parallel group clinical trial.
The investigators will screen 343 subjects, with an objective to enroll 144 high risk infants with the PAI-1 risk genotype, who are born between January 1 and May 15, will be randomized (July 15th- August 15th) to one of two treatment groups through the viral season (August 15th to March 15th in 3 yearly cohorts.
The treatment groups will be either oral isoflavone supplement (at doses similar to that seen in soy formula) or a matching placebo.
Screening will occur January through July of each year, with genotyping occurring at the first visit, and assumption of care of individuals with the risk genotype after randomization.
There will be a study run in period until the second week of July at which time subjects will be randomized.
At randomization, the investigators will assume the care of the children for all wheezing illnesses.
The subjects will have either virtual or in person visits for each of the next 6 visits, followed by an in-person visit at the end of treatment.
The subjects will also come in for in-person visits at times of viral illnesses.
At randomization, end of treatment, viral illness, and end of study the subjects will have nasal swabs and nasosorption carried out.
Blood draws will occur at randomization, end of treatment, and the end of study visit.
Stool will be collected for microbiome assessment at randomization, the 3rd or 4th month of treatment, the end of treatment, and the end of the study at the end of the observation year.
The study will also measure infant pulmonary function using a wearable device to assess expiratory variability overnight.
This will be measured at randomization, viral illness, end of treatment, and at the end of the study after the 1 year observation period.
The treatment period will run from August to March 15th for each participant, with a 1 year observation period after this.
The study will recruit over 3 consecutive years.
Study Type
Interventional
Enrollment (Estimated)
144
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sarah Godley, RN
- Phone Number: 312 227 6010
- Email: sgodley@luriechildrens.org
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University Feinberg School of Medicine
-
Contact:
- Michelle Kominarek, MD
-
Chicago, Illinois, United States, 60611
- Recruiting
- Ann and Robert H Lurie Childrens Hospital of Chicago
-
Principal Investigator:
- Rajesh Kumar, MD
-
Contact:
- Rajesh Kumar, MD
- Phone Number: 312-227-6010
-
Sub-Investigator:
- Abigail Lang, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 months to 6 months (Child)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Parent guardian must be able to understand and provide informed consent.
- Age: Term children (≥37 weeks gestational age) born from January 1 to May 15 of the recruitment year.
High risk of asthma: As determined by one or more of the following:
- A history of uni- or bi-parental asthma with onset in childhood by parent self report, OR
- Uni- or bi-parental asthma with onset after childhood along with the presence of one or more other comorbid atopic condition including allergic rhinitis, atopic dermatitis, or food allergy, OR
- atopic dermatitis in the child determined by parent report of a physician diagnosis
- Genotype: Either homozygous or heterozygous for the PAI-1 risk allele (i.e. 4G4G or 4G5G).
Exclusion Criteria:
- Inability or unwillingness of a parent guardian to give written informed consent or comply with study protocol.
- Parents who will not include either a puree or some form of bottle feeding such that the infant would be able to take the investigational product in a puree or a liquid (expressed breast milk, supplemental formula, or a small amount of water).
- Currently on a soy based formula.
- Breastfeeding mothers who are taking soy supplements or soy enriched foods more than 2 times a week and will not stop this level of ingestion while breastfeeding.
- On treatment for recurrent wheezing such as regular inhaled steroids.
- The subject may not have the following specific contraindications: known congenital thyroid disease, or a history of estrogen sensitive clinically relevant mutations in the family (such as BRACA1).
Medication use
- Maternal use of tamoxifen in pregnancy or if breastfeeding
- Use of immunomodulatory medications such at methotrexate, mycophenolate, azathioprine, or other immunomodulatory agent in the mother if breastfeeding or in the infant.
- Use of another investigational agent in the last 30 days prior to randomization.
- Current, parent reported, diagnosis of mental illness or current, diagnosed or self-reported drug or alcohol abuse (in the primary caregiver) that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
- Known allergy to soy protein (either by reported allergy or skin testing to soy prior to randomization) or reported allergy to NovaSoy, from which the investigational product is compounded.
- The infant is currently participating in another asthma-related pharmaceutical study or intervention study or who have participated in another asthma-related pharmaceutical study or intervention study in the month prior to enrollment.
- Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
- Any chronic condition requiring use of systemic corticosteroids or another immunomodulating agent at screening or run-in, and during the course of the study
Non-adherence:
- Inability / unwillingness of the parents to induce the child to swallow study medication
- Unwillingness of the parents to allow the staff to perform baseline measurements
- Living with a foster parent as a ward of the state.
- Caregiver does not have access to a phone (needed for scheduling appointments or responding to questionnaires);
- Plan(s) for the family to move from the area during the study period;
- The participant's caretaker does not primarily speak English or Spanish
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Soy isoflavone
Soy isoflavone powder dosed in puree or liquid twice daily
|
Soy isoflavone supplement (Novasoy) that contains isoflavones (genistein, daidzein, glycetein) given at a dose of genistein aglycone equivalents to provide the genistein dosing of 22.6 mg/day for children aged 2-10 months, and 30.3 mg/day children aged 10-24 months
Other Names:
|
Placebo Comparator: Placebo
Matching placebo powder dosed in puree or liquid twice daily
|
A matching placebo also administered twice daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
wheezing episodes
Time Frame: 7 months
|
Number of episodes of wheezing - based on numbers of reported episodes of illness associated with wheezing over the treatment period.
|
7 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Expiratory variability index
Time Frame: from week 0 (randomization) to week 30 (end of treatment) and from week 0 (randomization) to week 88 (end of study)
|
Infant pulmonary function assessed by measurement of the Expiratory Variability Index change from baseline
|
from week 0 (randomization) to week 30 (end of treatment) and from week 0 (randomization) to week 88 (end of study)
|
safety and tolerability
Time Frame: from week 0 (randomization) to week 88 (end of study)
|
Number and grade of adverse events by treatment arm
|
from week 0 (randomization) to week 88 (end of study)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Other measures of wheezing and respiratory morbidity
Time Frame: week 88 - end of study visit
|
modified asthma predictive index at the end of the study
|
week 88 - end of study visit
|
sensitization to allergens
Time Frame: Week 30 at the end of treatment
|
The proportion of participants sensitized to indoor allergens (assessed by measurement of Dermatophygoides farinae, Dermatophygoides pteronyssinius, dog, cat, cockroach, mouse sIgE) and food allergens (milk, egg, peanut, wheat, and soy)
|
Week 30 at the end of treatment
|
work disruption due to child's asthma
Time Frame: Week 0 to week 30
|
The ratio of the work hours missed due to child's asthma over the numbers of work hours in the past 14 days in active vs placebo groups at each visit.
|
Week 0 to week 30
|
Daycare/ pre-school Absences due to the child's asthma
Time Frame: from randomization (week 0) to the end of treatment (week 30) and secondarily to the end of the observation period (week 88)
|
The ratio of the number of school days missed over the number of school days in session in active vs placebo participants
|
from randomization (week 0) to the end of treatment (week 30) and secondarily to the end of the observation period (week 88)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Rajesh Kumar, MD, Ann and Robert H. Lurie Children's Hospital of Chicago
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 15, 2024
Primary Completion (Estimated)
May 30, 2026
Study Completion (Estimated)
September 30, 2028
Study Registration Dates
First Submitted
December 20, 2022
First Submitted That Met QC Criteria
December 20, 2022
First Posted (Actual)
December 29, 2022
Study Record Updates
Last Update Posted (Actual)
April 2, 2024
Last Update Submitted That Met QC Criteria
March 29, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAUSE-LCH-001
- U01AI160018-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
At present, the investigators plan to make deidentified data available as per NIH policy at 3 years after the completion of the study.
This will not include any identifying information but will include all the primary outcome data and the participant individual level data that were included in the analyses including relevant covariates.
It is planned that the investigators will use AccessClinicalData@NIAID for this purpose.
IPD Sharing Time Frame
The investigators anticipate that data will be made publicly available 3 years after completion of the study.
IPD Sharing Access Criteria
Investigators will be able to apply for use of the data and this will be reviewed by a committee, to prevent duplicative efforts.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma in Children
-
Istituto di Farmacologia Traslazionale - sede di...Not yet recruitingAsthma in Children | Children, Only | Serious Game
-
University of FloridaNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingAsthma in ChildrenUnited States
-
ResMedCompletedAsthma in ChildrenUnited States
-
University of WashingtonNational Institute of Environmental Health Sciences (NIEHS); National Institute... and other collaboratorsCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Duke UniversityRecruitingAsthma in ChildrenUnited States
-
Rambam Health Care CampusCompleted
-
Shaoxing Maternity and Child Health Care HospitalRecruiting
-
University of LiverpoolNot yet recruiting
Clinical Trials on Soy isoflavone
-
National Cancer Institute (NCI)CompletedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Carcinoma | Tongue... and other conditionsUnited States
-
American Lung Association Asthma Clinical Research...National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Completed
-
National Nutrition and Food Technology InstituteCompleted
-
National Nutrition and Food Technology InstituteUnknownPeritoneal Dialysis PatientsIran, Islamic Republic of
-
National Health Research Institutes, TaiwanGenovate Biotechnology Co., Ltd.,; Taiwan Biotech Co., Ltd.Unknown
-
Laboratoires ArkopharmaUnknown
-
University of FloridaCompletedBiochemical Recurrent Prostate CancerUnited States
-
Imam Abdulrahman Bin Faisal UniversityCompletedBone Density Increased | Bone Density, Low | Soy Isoflavone EffectSaudi Arabia
-
Mayo ClinicPhysicians Pharmaceuticals, Inc.Completed
-
Northwestern UniversityRespiratory Health Association of Metropolitan ChicagoCompleted